

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-143)	POSOLEUCCEL
PRONUNCIATION	poe" soe loo' sel
THERAPEUTIC CLAIM	Treatment of opportunistic viral infections such as Hemorrhagic cystitis caused by the BK virus
DESCRIPTION	

Viralym-M™ is a once-stimulated, non-genetically modified T Cell product that is highly polyclonal with potent broad-spectrum activity against six clinically significant viruses (BK virus, Adenovirus, Cytomegalovirus, Human Herpesvirus 6, Epstein-Barr Virus, and JC Virus) that recognize multiple epitopes presented in the context of multiple HLA alleles.

Viralym-M™ cells are manufactured by co-culting peripheral blood mononuclear cells (PBMCs) from seropositive donors with viral pepmixes (15-mer peptides overlapping by 11 amino acids spanning immunogenic antigens from each target virus: BK/JC virus (VP1 and large T), Adv (Hexon and Penton), CMV (IE1 and pp65), EBV (LMP2, EBNA1, BZLF1) and HHV6 (U90, U11 and U14) and IL4 and IL7 in complete medium in a bioreactor.

TRADEMARK	Viralym-M™
SPONSOR	ViraCyte
CODE DESIGNATIONS	None
UNII	UZ54216N0Y
WHO NUMBER	11363

SCS